Background: Hepatocellular Carcinoma (HCC) is the second cause of cancer-related death worldwide. The late diagnosis and the difficulty in predicting the tumor evolution could explain the high mortality rate. Recently the potential role of miRNAs as prognostic biomarker has witnessed an increasing interest, owing to the non-invasive nature of miRNA-based screening assays. Aim: To identify potential circulating miRNAs as biomarkers for monitoring the disease and therapy response in HCC. Methods: 15 consecutive patients with early/intermediated stage HCC were enrolled and treated according to the ESSL/AASLD practice guidelines. Patients were staged at time 0 and 1 month from therapy with CT scan and/or MRI. Pax-gene Blood RNA tubes and Vacuette tubes where used to collect total blood and serum. Small RNAs were hybridized on Affymetrix GeneChip miRNA arrays 3.0. qRT-PCR was used for miRNA validation in an independent cohort of 15 matched patients. The Kaplan-Meier model was used to estimate disease-free survival (DFS), the longest follow-up was 20 month. Results: We identified distinctive circulating miRNA signatures characterizing patients with shorter DSF vs longer (<3 vs ≥7 months). The validation of miR-106b highlighted a correlation between mir-106b levels and treatment response (P < 0.001), Kaplan-Meier estimates correlated the high mir-106b expression with the longest DFS (P < 0.0038). MiRNA-106b was significantly correlated with the with BCLC staging A1 and A2 (P < 0.001). The comparison between miRNA signatures in blood and serum at T0 and T1 identified specific miRNA alterations after therapy. Interestingly most of the differentially expressed miRNA are still uncharacterized. This is the first evidence of their expression in HCC.
CIRCULATING MICRORNA IN HEPATOCELLULAR CARCINOMA AS PROGNOSTIC BIOMARKERS / Pascut, D; Krmac, H; Mezzina, N; Patti, R; Licastro, D; Dal Monego, S; Abazia, C; Petraccia, L; Masutti, F; Croce, Sl; Calligaris, R; Tiribelli, C.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 48:(2016), pp. E23-E23. (Intervento presentato al convegno 49th A.I.S.F. – Italian Association for the Study of the Liver – Annual Meeting 2016 tenutosi a Rome) [10.1016/j.dld.2015.12.061].
CIRCULATING MICRORNA IN HEPATOCELLULAR CARCINOMA AS PROGNOSTIC BIOMARKERS
Petraccia L;
2016
Abstract
Background: Hepatocellular Carcinoma (HCC) is the second cause of cancer-related death worldwide. The late diagnosis and the difficulty in predicting the tumor evolution could explain the high mortality rate. Recently the potential role of miRNAs as prognostic biomarker has witnessed an increasing interest, owing to the non-invasive nature of miRNA-based screening assays. Aim: To identify potential circulating miRNAs as biomarkers for monitoring the disease and therapy response in HCC. Methods: 15 consecutive patients with early/intermediated stage HCC were enrolled and treated according to the ESSL/AASLD practice guidelines. Patients were staged at time 0 and 1 month from therapy with CT scan and/or MRI. Pax-gene Blood RNA tubes and Vacuette tubes where used to collect total blood and serum. Small RNAs were hybridized on Affymetrix GeneChip miRNA arrays 3.0. qRT-PCR was used for miRNA validation in an independent cohort of 15 matched patients. The Kaplan-Meier model was used to estimate disease-free survival (DFS), the longest follow-up was 20 month. Results: We identified distinctive circulating miRNA signatures characterizing patients with shorter DSF vs longer (<3 vs ≥7 months). The validation of miR-106b highlighted a correlation between mir-106b levels and treatment response (P < 0.001), Kaplan-Meier estimates correlated the high mir-106b expression with the longest DFS (P < 0.0038). MiRNA-106b was significantly correlated with the with BCLC staging A1 and A2 (P < 0.001). The comparison between miRNA signatures in blood and serum at T0 and T1 identified specific miRNA alterations after therapy. Interestingly most of the differentially expressed miRNA are still uncharacterized. This is the first evidence of their expression in HCC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
